Education
About Us
Working with TipRanks
Follow Us
Beijing Airdoc Technology Co. Ltd. Class H (HK:2251)
:2251
Top Page
Beijing Airdoc Technology Co. Ltd. Class H
(2251)
Select Model
Select Model
Rating:40Neutral
Price Target:
HK$12.50
▲(0.48% Upside)
The overall stock score is primarily impacted by the company's weak financial performance, characterized by declining revenues, persistent losses, and negative cash flows. Technical analysis indicates bearish momentum, with the stock trading below key moving averages. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, further weighing down the score.
Positive Factors
Strong Equity Position
A high equity ratio indicates low financial leverage, providing stability and reducing financial risk, which is beneficial for long-term sustainability.
AI-Driven Healthcare Solutions
Leveraging AI in healthcare offers a competitive advantage by enhancing diagnostic accuracy and efficiency, positioning the company well in a growing market.
Subsidiary Acquisition
Consolidating the subsidiary could streamline operations and improve financial reporting, potentially leading to better strategic alignment and resource allocation.
Negative Factors
Declining Revenue
A substantial drop in revenue indicates challenges in market demand or competitive positioning, which could hinder growth and profitability.
Negative Cash Flow
Inability to generate positive cash flow raises sustainability concerns, limiting the company's ability to invest in growth and manage financial obligations.
Leadership Changes
Frequent leadership changes can disrupt strategic continuity and may affect the company's ability to execute long-term plans effectively.
Beijing Airdoc Technology Co. Ltd. Class H (2251) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.14B
Dividend YieldN/A
Average Volume (3M)61.23K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth-32.17%
EPS Growth-1.20%
CountryHK
Employees248
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.02
Shares Outstanding103,568,016
10 Day Avg. Volume99,440
30 Day Avg. Volume61,230
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.93
Price to Sales (P/S)7.56
P/FCF Ratio-7.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Beijing Airdoc Technology Co. Ltd. Class H Business Overview & Revenue Model
Company DescriptionBeijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-based software as a medical device for auxiliary diagnosis of diabetic retinopathy; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; and Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia, retinal detachment, glaucoma detection, cataracts detection, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. The company also provides health risk assessment solutions to detect risk indicators, such as various lesions and diseases, hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation, and arteriosclerosis in a range of healthcare environments, including health checkup centers, community clinics, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices, including fundus cameras. The company was incorporated in 2015 and is headquartered in Beijing, China.
How the Company Makes MoneyBeijing Airdoc Technology Co. Ltd. generates revenue through multiple streams, primarily from the sale of its AI-powered medical devices and software solutions to hospitals, clinics, and healthcare providers. The company's revenue model is built on direct sales, subscription fees for its cloud-based services, and licensing agreements for its proprietary technology. Additionally, Airdoc has established strategic partnerships with healthcare institutions and technology firms, which help expand its market reach and enhance its product offerings. The company also benefits from government health initiatives and funding aimed at improving healthcare accessibility and efficiency in diagnostics.
Beijing Airdoc Technology Co. Ltd. Class H Financial Statement Overview
Summary
Beijing Airdoc Technology Co. Ltd. is facing significant financial challenges. The company struggles with declining revenues, persistent losses, and inefficiencies in operations. Despite a strong equity base, the lack of profitability and negative cash flows pose serious risks to financial stability. Strategic improvements are necessary to enhance revenue growth and operational efficiencies.Income Statement
The company has experienced significant declines in revenue with a 23.35% decrease from 2023 to 2024. Gross profit margins remain relatively healthy at 55.42% in 2024, but net income is deeply negative, reflecting ongoing profitability challenges. The negative EBIT and EBITDA margins indicate operational inefficiencies and high costs relative to revenue.20
Very Negative
Balance Sheet
The company maintains a strong equity position with an equity ratio of 89.87% in 2024, indicating low financial leverage. However, the negative return on equity reflects losses and underutilization of equity capital. Total liabilities remain low, which reduces financial risk, but persistent negative net income impacts overall financial health.35
Negative
Cash Flow
The company's cash flows are concerning, with zero operating and free cash flow in 2024. The inability to generate positive cash flow from operations raises sustainability concerns. Historical cash flows have been volatile, with significant negative free cash flow, highlighting challenges in managing cash effectively.15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 146.37M | 156.37M | 203.96M | 113.66M | 115.18M | 47.67M |
| Gross Profit | 97.02M | 86.68M | 125.13M | 55.85M | 70.24M | 29.09M |
| EBITDA | -175.75M | -259.70M | -113.36M | -159.64M | -126.73M | -51.97M |
| Net Income | -176.63M | -255.46M | -132.53M | -180.00M | -142.63M | -80.06M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.41B | 1.68B | 1.74B | 1.89B | 435.75M |
| Cash, Cash Equivalents and Short-Term Investments | 618.65M | 774.82M | 1.14B | 1.41B | 1.78B | 374.70M |
| Total Debt | 12.71M | 31.88M | 9.37M | 8.01M | 8.20M | 519.00K |
| Total Liabilities | 93.78M | 134.86M | 127.13M | 68.59M | 74.19M | 27.30M |
| Stockholders Equity | 1.27B | 1.27B | 1.54B | 1.67B | 1.82B | 408.21M |
Cash Flow | ||||||
| Free Cash Flow | -90.28M | -167.51M | 8.02M | -392.55M | -140.11M | -64.77M |
| Operating Cash Flow | -97.04M | -165.43M | 23.37M | -380.44M | -112.09M | -42.86M |
| Investing Cash Flow | 234.62M | -11.34M | -385.14M | -154.43M | -22.01M | 91.69M |
| Financing Cash Flow | -3.62M | -33.31M | -18.53M | -17.14M | 1.55B | 240.63M |
Beijing Airdoc Technology Co. Ltd. Class H Technical Analysis
Negative
12.44
Price Trends
11.90
Negative
12.73
Negative
12.68
Negative
Market Momentum
-0.08
Positive
40.27
Neutral
9.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2251, the sentiment is Negative. The current price of 12.44 is above the 20-day moving average (MA) of 12.23, above the 50-day MA of 11.90, and below the 200-day MA of 12.68, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 40.27 is Neutral, neither overbought nor oversold. The STOCH value of 9.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2251.
Beijing Airdoc Technology Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$1.90B | 10.05 | 7.31% | 9.29% | -3.19% | -20.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.89B | -16.14 | -6.41% | 1.20% | 2.05% | -285.88% | |
46 Neutral | HK$565.34M | -0.69 | -47.91% | 2.15% | -18.98% | -164.82% | |
45 Neutral | HK$6.16B | -63.84 | -2.23% | ― | -4.99% | 47.18% | |
45 Neutral | HK$1.87B | -9.46 | -55.33% | ― | -100.00% | 30.68% | |
40 Neutral | HK$1.14B | -6.15 | -12.97% | ― | -32.17% | -1.20% |
* Healthcare Sector Average
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
11.52
0.90
8.47%
HK:2158
Yidu Tech, Inc.
5.79
0.80
16.03%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.69
-0.14
-4.95%
HK:2325
Yunkang Group Limited
0.91
-4.39
-82.83%
HK:3309
C-MER Eye Care Holdings Limited
1.53
-0.36
-19.05%
HK:3681
SinoMab Bioscience Ltd.
1.36
0.35
34.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.